CommercialCoverageMedium impact
08.00.34x, Intravenous Infliximab and Related Biosimilars
Independence Blue Cross·Rheumatology, Gastroenterology, Dermatology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has updated their pharmacy policy for intravenous infliximab and related biosimilar medications, effective January 1, 2026. This policy change affects billing and coverage requirements for these specialty infusion medications used primarily in treating autoimmune conditions.
Action Required
Before January 1, 2026: Billing team must review the complete updated policy at the provided URL to understand specific changes to infliximab and biosimilar coverage requirements. Update prior authorization protocols and billing procedures for IV infliximab treatments according to the new policy guidelines.